News
Amgen and Kyowa Kirin agree to jointly develop eczema med
Amgen and Kyowa Kirin have signed an agreement to jointly develop and commercialise KHK4083, a monoclonal antibody (mAb) in development for the treatment of atopic dermatitis – the most common form of eczema.